Investigating the trajectory of functional disability in systemic sclerosis: group-based trajectory modelling of the Health Assessment Questionnaire-Disability Index.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
08 2024
Historique:
received: 07 11 2023
accepted: 08 01 2024
medline: 17 8 2024
pubmed: 17 8 2024
entrez: 17 8 2024
Statut: ppublish

Résumé

To identify the trajectories and clinical associations of functional disability in systemic sclerosis (SSc). Australian Scleroderma Cohort Study (ASCS) participants meeting ACR/EULAR criteria for SSc recruited within 5 years of disease onset, with ≥2 Health Assessment Questionnaire-Disability Index (HAQ-DI) scores were included. Group based trajectory modelling (GBTM) was used to identify the number and shape of HAQ-DI trajectories. Between group comparisons were made using the chi-squared test, two-sample t-test or Wilcoxon rank-sum test as appropriate. Multiple logistic regression was used to identify features associated with trajectory group membership. Survival analyses were performed using Kaplan Meier and Cox proportional hazard modelling. We identified two HAQ-DI trajectory groups within 426 ASCS participants with incident SSc: low-stable disability (n=221, 52%), and high-increasing disability (n=205, 48%). Participants with high-increasing disability were older at disease onset, more likely to have diffuse SSc (dcSSc), cardiopulmonary disease, multimorbidity, digital ulcers, and gastrointestinal involvement (all p≤0.01), as was use of immunosuppression (p<0.01). Multimorbidity was associated with high-increasing trajectory group membership (OR3.1, 95%CI1.1-8.8, p=0.04); independently, multiple SSc features were also strongly associated including dcSSc (OR2.3, 95%CI1.3-4.2, p<0.01), proximal weakness (OR7.3, 95%CI2.0-27.1, p<0.01) and joint contractures (OR2.7, 95%CI1.3-5.3, p<0.01). High-increasing physical disability was associated with an almost two-fold increased risk of mortality (HR1.9, 95%CI1.0-3.8, p=0.05), and higher symptom burden. Two trajectories of functional disability in SSc were identified. Those with high-increasing functional disability had a distinct clinical phenotype and worse survival compared to those with low-stable functional disability. These data highlight the pervasive nature of physical disability in SSc, and its prognostic importance.

Identifiants

pubmed: 39152747
pii: 20539
doi: 10.55563/clinexprheumatol/9erk5j
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1581-1589

Auteurs

Jessica L Fairley (JL)

The University of Melbourne, Victoria, and St. Vincent's Hospital Melbourne, Victoria, Australia.

Dylan Hansen (D)

St. Vincent's Hospital Melbourne, Victoria, Australia.

Murray Baron (M)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, and McGill University, Montreal, Canada.

Susanna Proudman (S)

University of Adelaide, South Australia, and Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Joanne Sahhar (J)

Monash Health, Melbourne, Victoria, and Monash University, Melbourne, Victoria, Australia.

Gene-Siew Ngian (GS)

Monash Health, Melbourne, Victoria, AustraliaMonash University, Melbourne, Victoria, Australia.

Jenny Walker (J)

Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Lauren V Host (LV)

Fiona Stanley Hospital, Perth, Western Australia, Australia.

Kathleen Morrisroe (K)

The University of Melbourne, Victoria, and St. Vincent's Hospital Melbourne, Victoria, Australia.

Wendy Stevens (W)

St. Vincent's Hospital Melbourne, Victoria, Australia.

Mandana Nikpour (M)

The University of Melbourne, Victoria; St. Vincent's Hospital Melbourne, Victoria; The University of Sydney School of Public Health, Sydney, New South Wales, and Royal Prince Alfred Hospital Sydney, New South Wales, Australia.

Laura Ross (L)

The University of Melbourne, Victoria, and St. Vincent's Hospital Melbourne, Victoria, Australia. laura.ross@unimelb.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH